Etoposide, ifosfamide and cisplatin (VIP) plus concurrent radiation therapy for previously untreated limited small cell lung cancer (SCLC): a Hoosier Oncology Group (HOG) phase II study
Keyword(s):
Phase Ii
◽
2009 ◽
Vol 4
(4)
◽
pp. 527-533
◽